RecruitingAtypical Hemolytic-Uremic Syndrome
Atypical Hemolytic-Uremic Syndrome (aHUS) Registry
Eligible age
All ages
Accepts
All genders
Locations
9 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
Post-marketing safety data on patients treated and untreated with eculizumab or ravulizumab.
Sponsor: Alexion Pharmaceuticals, Inc.
You may qualify if…
- ✓ Male or female patients of any age, including minors, who have been diagnosed with aHUS
- ✓ Patients with or without an identified complement pathogenic variant or anti-complement factor antibody
- ✓ Able to give written informed consent. Patient or patient's parent/legal guardian must be willing and able to given written informed consent and the patient (if minor) must be willing to give written informed assent \[if applicable as determined by the central Institutional Review Boards/Independent Ethics Committees (IRB/IEC)\].
- ✓ ADAMTS13 \> 5%, if performed.
You may not qualify if…
- ✕ Hemolytic Uremic Syndrome (HUS) only due to Shiga Toxin producing Escherichia coli (STEC).
- ✕ Unable to give written informed consent. Patient or patient's parent/legal guardian unable to give written informed consent. Patient (if minor) unable to give written informed assent (if applicable as determined by the central Institutional Review Boards/Independent Ethics Committees \[IRB/IEC\]).
Where it's recruiting
Colorado
Aurora
District of Columbia
Washington D.C.
Florida
Gainesville
Georgia
Atlanta
Illinois
Chicago
Massachusetts
Boston
Missouri
St Louis
North Carolina
Winston-Salem
Ohio
Columbus
Source: ClinicalTrials.gov · NCT01522183 · last updated 2025-09-16